Saturday, October 28, 2017
Meet the Moffitt startup that helps doctors find the best treatments for cancer patients

A biotech startup founded by a Moffitt Cancer Center researcher and a medical business expert on his team has begun commercial development of technology that helps oncologists find the best treatments for their cancer patients.  ..

Read More
Wednesday, October 11, 2017
Moffitt Researchers Discover New Targets for Approved Cancer Drug

A team of researchers at Moffitt Cancer Center used cellular drug screening, functional proteomics and computer-based modeling to determine whether drugs with well-known targets may be repurposed for use against other biological targets.  ..

Read More
Wednesday, September 06, 2017
Moffitt: New Study Finds Improved Vaccine That Protects against Nine Types of HPV is Highly Effective

Thanks to an international effort to improve the vaccine, the medical community is one step closer to preventing more HPV-associated diseases. The researchers, including those from Moffitt Cancer Center, published the final results of a study showing the newest vaccine is highly effective at preventing HPV infection and disease.  ..

Read More
Tuesday, August 08, 2017
Moffitt: New Research Shows the Power of Radiomics to Improve Precision Medicine

In a collaborative project, researchers at the Moffitt Cancer Center and Dana-Farber Cancer Institute investigated the emerging field of radiomics has the potential to improve precision medicine by non-invasively assessing the molecular and clinical characteristics of lung tumors. ..

Read More
Monday, July 17, 2017
Moffitt:Radiation Therapy Prior to Surgery Reduces the Risk of Secondary Tumors in Early-Stage Breast Cancer Patients

Moffitt Cancer Center researchers launched a first of its kind study comparing the long-term benefits of radiation therapy in women with breast cancer either before surgery (neoadjuvant) or after surgery (adjuvant).  ..

Read More
Saturday, July 01, 2017
Moffitt Cancer Center Targets Tumors by Using More Precise Radiation Method

Clinicians at Moffitt Cancer Center are better able to aim radiation therapy directly at tumors, while avoiding surrounding tissues by using MRI-guidance. ..

Read More
Wednesday, June 14, 2017
Experimental Drug Co-Developed by Moffitt Cancer Center Researcher Shows Promise

A collaboration between Saïd M. Sebti, Ph.D., chair of Moffitt Cancer Center’s Drug Discovery Department, and Michele Pagano, M.D., chair of the Department of Biochemistry and Molecular Pharmacology at New York University’s Langone Medical Center, found that the drug, geranylgeranyltransferase inhibitor GGTI-2418 suppresses a new defective PTEN cancer pathway discovered by Pagano’s group. ..

Read More
Monday, May 29, 2017
Moffitt Researchers Demonstrate Mathematical Modeling Can Identify Ways to Limit Aggressive Tumor Cell Growth

Cancers can be viewed as complex dynamic systems because they have many interacting parts that can change over time and space. Perhaps the most well-known complex dynamic system is the weather and, similar to weather forecasting, researchers in the Integrated Mathematical Oncology Department at the Moffitt Cancer Center are using mathematical methods to account for many variables in the search for new ways to understand and control cancer.  ..

Read More
Tuesday, March 28, 2017
New Study Identifies 12 New Genetic Variants Linked to Ovarian Cancer

There is new proof your genes may hold the key to whether or not you have a higher risk of developing cancer. Moffitt Cancer Center researchers took part in a major international study published in Nature Genetics that identified 12 new genetic variants associated with an increased risk of developing epithelial ovarian cancer, the most common and dangerous type of the disease.  ..

Read More
Thursday, February 16, 2017
Mayo Clinic to test vaccine designed to provide immune response against early breast lesions

Keith Knutson, Ph.D., director of the Discovery and Translation Labs Cancer Research Program at Mayo Clinic’s campus in Florida, has received a $3.7 million grant from the U.S. Department of Defense to conduct a phase II clinical trial that will test a vaccine designed to establish lifelong immunity against development of these precancerous lesions. ..

Read More